Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin

Epilepsy Research

Volumn 47, Issue 1-2, 2001, Pages 55-63

  Ragueneau Majlessi, I ^a   Levy, R H ^a   Meyerhoff, C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AAI Deutschland GmbH and Co KG   (Germany)

Author keywords

Cytochrome P450; Drug interactions; Epilepsy; Levetiracetam; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ETIRACETAM; PLACEBO; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATAXIA; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; NAUSEA; NERVOUSNESS; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ANTICONVULSANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PIRACETAM; WARFARIN;

EID: 0034757376     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00293-5     Document Type: Article

References (15)

1. Comments on the note for guidance on bioavailability and bioequivalence in the European Union
2. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: Mechanisms, clinical significance, and avoidance
3. Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy
4. A review of enzyme induction of warfarin metabolism with recommendations for patient management
5. Clinically important drug interactions with anticoagulants. An update
6. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe
7. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients
8. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
9. Antiepileptic drugs. A review of clinically significant drug interactions
10. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
11. Bioavailability and bioequivalence requirements in the European community
12. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
13. Drug interactions in human neuropathic pain pharmacotherapy
14. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world